Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) Insider Sells 101,409 Shares of Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) insider Johannes Jacob Piete Kastelein sold 101,409 shares of the company’s stock in a transaction on Monday, March 9th. The stock was sold at an average price of $30.29, for a total transaction of $3,071,678.61. Following the completion of the transaction, the insider directly owned 69,302 shares of the company’s stock, valued at approximately $2,099,157.58. The trade was a 59.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Johannes Jacob Piete Kastelein also recently made the following trade(s):

• On Friday, March 6th, Johannes Jacob Piete Kastelein sold 94,124 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $30.32, for a total value of $2,853,839.68.
• On Thursday, March 5th, Johannes Jacob Piete Kastelein sold 104,467 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $30.30, for a total value of $3,165,350.10.
• On Friday, February 20th, Johannes Jacob Piete Kastelein sold 45,481 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $35.31, for a total value of $1,605,934.11.
• On Monday, January 5th, Johannes Jacob Piete Kastelein sold 6,000 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $33.25, for a total value of $199,500.00.

NewAmsterdam Pharma Stock Performance

NASDAQ NAMS traded up $0.91 during trading on Monday, hitting $30.77. The stock had a trading volume of 761,265 shares, compared to its average volume of 827,191. The company has a market capitalization of $3.54 billion, a PE ratio of -17.79 and a beta of 0.04. NewAmsterdam Pharma Company N.V. has a 12 month low of $14.06 and a 12 month high of $42.00. The company’s 50-day moving average price is $33.48 and its two-hundred day moving average price is $33.32.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings data on Wednesday, February 18th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.23). The business had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.92 million. NewAmsterdam Pharma had a negative return on equity of 26.67% and a negative net margin of 906.22%. As a group, equities analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on NAMS shares. Guggenheim raised their price target on NewAmsterdam Pharma from $41.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday, February 19th. Stifel Nicolaus boosted their target price on shares of NewAmsterdam Pharma from $44.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. Needham & Company LLC increased their price target on shares of NewAmsterdam Pharma from $46.00 to $48.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. Wall Street Zen downgraded shares of NewAmsterdam Pharma from a “hold” rating to a “sell” rating in a research report on Saturday, February 21st. Finally, Leerink Partners restated an “outperform” rating and set a $55.00 price objective on shares of NewAmsterdam Pharma in a research note on Tuesday, January 6th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, NewAmsterdam Pharma currently has an average rating of “Moderate Buy” and a consensus target price of $47.10.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in NAMS. Seven Fleet Capital Management LP acquired a new stake in NewAmsterdam Pharma during the 4th quarter valued at $140,000. Empowered Funds LLC bought a new position in shares of NewAmsterdam Pharma in the fourth quarter valued at about $85,000. XTX Topco Ltd lifted its stake in shares of NewAmsterdam Pharma by 1,714.1% during the 4th quarter. XTX Topco Ltd now owns 137,492 shares of the company’s stock worth $4,823,000 after buying an additional 129,913 shares during the last quarter. Virtus Investment Advisers LLC boosted its holdings in shares of NewAmsterdam Pharma by 32.0% during the 4th quarter. Virtus Investment Advisers LLC now owns 7,142 shares of the company’s stock worth $251,000 after buying an additional 1,731 shares during the period. Finally, Twinbeech Capital LP acquired a new position in NewAmsterdam Pharma in the 4th quarter valued at about $961,000. 89.89% of the stock is owned by institutional investors and hedge funds.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.